Core Viewpoint - The company has not yet applied its main business product materials in the robotics field and is considering future commercialization and collaboration in related areas based on R&D and market conditions [1] Group 1 - The company has developed multiple ophthalmic medical device products based on its existing technology platform, but none have entered the smart glasses market as of now [1] - The company currently lacks the latest authoritative third-party statistics on its domestic market share for its main business products [1] - In the intraocular lens sector, the company's product volume ranks first according to data disclosed by national procurement [1] Group 2 - The company is continuously advancing the integration of quality resources through its own funds and industrial funds [1] - Future merger and acquisition plans will be evaluated based on market research results, technical feasibility, and other multidimensional factors, with strict adherence to regulatory disclosure requirements [1]

Core Viewpoint - The company aims to enhance its refined and intelligent management capabilities in the medical device distribution sector through the implementation of information systems, thereby strengthening its service attributes within the industry chain and promoting product diversification and integration with upstream and downstream partners [1][2]. Group 1: Business Overview - The company, Jianfa Zhixin, operates as a national high-value medical device distributor, focusing on direct sales and distribution of medical devices, as well as providing centralized operation services for medical consumables to end hospitals [1]. - The company has accumulated extensive operational and service experience in the medical device distribution field, establishing a certain market position through years of development and exploration of industry transformation [1][2]. Group 2: Future Development Plans - The company plans to ensure growth in sales of its core vascular intervention products while expanding sales in IVD, surgical, dental, and ophthalmic medical device sectors to solidify its foundation for scaled development [2]. - The company intends to strengthen collaboration with upstream manufacturers by providing efficient, flat, and centralized professional services across various dimensions such as channel access management, logistics management, inventory management, and information management [2]. - The company aims to explore opportunities in centralized operation management services for public hospital medical consumables, expanding direct sales and centralized operation services, and continuously developing and upgrading its SPD management system [2]. - The company will enhance its existing information systems to improve data analysis and lean management capabilities, providing robust support for business development [2]. Group 3: Financial Overview - The company plans to raise funds through its upcoming IPO to enhance its refined and intelligent management capabilities in medical device distribution, optimize its financial structure, and reduce operational risks [1]. - The company reported a significant increase in net cash flow from operating activities, amounting to 164 million yuan, a year-on-year increase of 539 million yuan [21]. - As of the first half of 2025, the company’s weighted average return on net assets was 8.84%, reflecting a decline of 0.35 percentage points compared to the same period last year [17]. Group 4: Revenue Composition - In 2024, the company's revenue composition included 99.666 billion yuan from vascular intervention, 38.468 billion yuan from surgical instruments, 23.39 billion yuan from IVD, 11.179 billion yuan from medical devices, and 4.997 billion yuan from other medical devices [6]. - The company’s revenue structure for 2023 showed similar trends, with vascular intervention contributing 92.046 billion yuan and surgical instruments contributing 30.7 billion yuan [8]. Group 5: Shareholder Structure - As of June 13, 2025, the largest shareholder of the company was Xiamen Jianfa Medical Health Investment Co., Ltd., holding 51.02% of the shares [51].

Core Viewpoint - Guangzhou's Yuexiu District has become a hub for pharmaceutical research and development, driven by continuous improvements in governance and business environment optimization [1][2]. Group 1: Industry Development - Yuexiu District has established itself as a leading area for clinical trials and has attracted major international CROs, with 15 top-tier hospitals and 5 national key laboratories in the biopharmaceutical sector [2][3]. - The district is focusing on the biopharmaceutical and health industry as part of Guangzhou's "12218" modern industrial system, promoting the integration of production, city, and talent [2][3]. Group 2: Economic Impact - The biopharmaceutical industry in Yuexiu is projected to exceed 40 billion yuan in added value by 2024, ranking second in the city, indicating a significant increase in industrial cluster capabilities [3]. - The transformation of the old properties in the district into a vibrant biopharmaceutical and health industry hub has attracted over 30 related enterprises, including CROs and innovative drug research firms [3][4]. Group 3: Policy and Support - Yuexiu District is committed to enhancing its service capabilities for enterprises by implementing targeted policies based on feedback from businesses and hospitals, ensuring effective support for talent development and corporate growth [3][4]. - The district has actively engaged in the organization of industry conferences, providing personalized services to participants, which has been well-received by industry leaders [5]. Group 4: Infrastructure and Resources - The district is improving its physical infrastructure by revitalizing properties around its major hospitals, converting spatial constraints into advantages for high-density development [4]. - Yuexiu is facilitating the flow of various resources, including policy, talent, and financial support, to foster innovation and entrepreneurship in the biopharmaceutical sector [4].